Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | AOC3 | Q16853 | 3/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | CASR | P41180 | 2/20 | 0.43 |
| ▸ | MTNR1A | P48039 | 2/20 | 0.41 |
| ▸ | MTNR1B | P49286 | 2/20 | 0.41 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.40 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.40 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.40 |
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.40 |
| ▸ | ACHE | P22303 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29061992 | 1.00 | KMT2A (0.49) | KMT2AAOC3L3MBTL1CASRMTNR1A | |
| SCHEMBL7410294 | 0.87 | KMT2A (0.47) | KMT2AAOC3L3MBTL1CASRMTNR1A | |
| SCHEMBL9230531 | 0.85 | KMT2A (0.51) | KMT2AAOC3L3MBTL1CASRMTNR1A | |
| SCHEMBL9230540 | 0.85 | KMT2A (0.48) | KMT2AAOC3L3MBTL1CASRMTNR1A | |
| SCHEMBL25159697 | 0.84 | PTGS1 (0.49) | KMT2A | |
| SCHEMBL7371959 | 0.84 | KMT2A (0.47) | KMT2AAOC3L3MBTL1CASRTAAR1 | |
| SCHEMBL5860346 | 0.84 | PTGS1 (0.49) | KMT2A | |
| SCHEMBL11161903 | 0.83 | KMT2A (0.40) | KMT2AL3MBTL1 | |
| SCHEMBL30167310 | 0.82 | KMT2A (0.43) | KMT2AAOC3L3MBTL1CASRMTNR1A | |
| SCHEMBL7311626 | 0.82 | KMT2A (0.43) | KMT2AAOC3L3MBTL1CASRMTNR1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116655482-B | Preparation method of gamma-aminobutyric acid derivatives | 贵州大学 | 2024-06-04 | — | — | CN | disclosed |
| CN-116655482-A | Preparation method of gamma-aminobutyric acid derivatives | 贵州大学 | 2023-08-29 | — | — | CN | disclosed |
| US-20190031615-A1 | 3-ETHYL-3-PHENYLAZEPANE DERIVATIVES HAVING MULTIMODAL ACTIVITY AGAINST PAIN | ESTEVE PHARMACEUTICALS, S.A. (ES) | 2019-01-31 | — | — | US | disclosed |
| US-20190031615-A1 | 3-ETHYL-3-PHENYLAZEPANE DERIVATIVES HAVING MULTIMODAL ACTIVITY AGAINST PAIN | ESTEVE PHARMACEUTICALS, S.A. (ES) | 2019-01-31 | — | — | US | disclosed |
| EP-3402779-A1 | 3-ETHYL-3-PHENYLAZEPANE DERIVATIVES HAVING MULTIMODAL ACTIVITY AGAINST PAIN | ESTEVE PHARMACEUTICALS, S.A. (ES) | 2018-11-21 | — | — | EP | disclosed |
| WO-2017121645-A1 | 3-ETHYL-3-PHENYLAZEPANE DERIVATIVES HAVING MULTIMODAL ACTIVITY AGAINST PAIN | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2017-07-20 | — | — | WO | disclosed |
| WO-2017121645-A1 | 3-ETHYL-3-PHENYLAZEPANE DERIVATIVES HAVING MULTIMODAL ACTIVITY AGAINST PAIN | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2017-07-20 | — | — | WO | disclosed |
| US-6358973-B1 | FOR THERAPY OF ALLERGIC OR INFLAMMATORY DISEASE | ZAMBON GROUP S.P.A. (IT) | 2002-03-19 | — | — | US | disclosed |
| EP-0822932-B1 | PIPERIDINE DERIVATIVES AS DIURETIC | UPJOHN CO (US) | 2000-07-12 | — | — | EP | disclosed |
| EP-0822932-A1 | PIPERIDINE DERIVATIVES AS DIURETIC | PHARMACIA & UPJOHN COMPANY (US) | 1998-02-11 | — | — | EP | disclosed |
| US-5716970-A | INCREASE EXCRETION OF URINE | PHARMACIA & UPJOHN COMPANY (US) | 1998-02-10 | — | — | US | disclosed |
| WO-1996033985-A1 | PIPERIDINE DERIVATIVES AS DIURETIC | PHARMACIA & UPJOHN COMPANY (US) | 1996-10-31 | — | — | WO | disclosed |
| US-5519022-A | α, α dialkylbenzyl derivatives | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1996-05-21 | — | — | US | disclosed |
| US-5288742-A | Lipoxygenase inhibitor | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1994-02-22 | — | — | US | disclosed |
| EP-0505122-A1 | Alpha, alpha-dialkylbenzyl derivatives | ZENECA LIMITED (GB) | 1992-09-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190031615-A1 | 3-ETHYL-3-PHENYLAZEPANE DERIVATIVES HAVING MULTIMODAL ACTIVITY AGAINST PAIN | OPRK1, OPRD1, OPRM1 | KMT2A 2939/4885AOC3 2382/4885L3MBTL1 4716/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.